These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8854508)

  • 41. Should the FDA regulate pharmacoeconomic studies?
    Robinson M
    HMO; 1996; 37(1):71-5. PubMed ID: 10159353
    [No Abstract]   [Full Text] [Related]  

  • 42. [Evaluation of the cost-effectiveness of thrombolytic therapy in acute myocardial infarct using tissue plasminogen activator or streptokinase:the Italian perspective].
    Lorenzoni R; Fattore G; Gensini G
    G Ital Cardiol; 1997 Jul; 27(7):721-6. PubMed ID: 9303862
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Medicines pricing singled out.
    Buchanan E
    S Afr Med J; 2004 May; 94(5):334. PubMed ID: 15211941
    [No Abstract]   [Full Text] [Related]  

  • 44. An Italian perspective: studying the cost-effectiveness of sofosbuvir before completion of national price negotiations.
    Messori A; Maratea D; Fadda V; Gatto R; Trippoli S
    Eur J Gastroenterol Hepatol; 2014 Jul; 26(7):813-4. PubMed ID: 24901827
    [No Abstract]   [Full Text] [Related]  

  • 45. Pharmacoeconomics: the new dismal science.
    Luchins DJ
    Adm Policy Ment Health; 2004 May; 31(5):425-7. PubMed ID: 15379388
    [No Abstract]   [Full Text] [Related]  

  • 46. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
    Hoomans T; van der Roer N; Severens JL; Delwel GO
    Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interpreting results from thrombolytic megatrials: distinguishing fact from fiction.
    Brophy JM
    Can J Cardiol; 1996 Jan; 12(1):89-92. PubMed ID: 8595575
    [No Abstract]   [Full Text] [Related]  

  • 48. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of government agencies regarding cost-effectiveness claims: FDA perspective.
    Temple R
    Am Heart J; 1999 May; 137(5):S75-7. PubMed ID: 10220602
    [No Abstract]   [Full Text] [Related]  

  • 49. Pharmaceuticals and Medical Devices: Cost Savings.
    Steiner DJ;
    Issue Brief Health Policy Track Serv; 2015 Dec; ():1-31. PubMed ID: 27116794
    [No Abstract]   [Full Text] [Related]  

  • 50. Healthcare reform and expenditure on drugs. The German situation.
    Ulrich V; Wille E
    Pharmacoeconomics; 1996; 10 Suppl 2():81-8. PubMed ID: 10163440
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions.
    Lipsy RJ
    Pharmacoeconomics; 1992 Apr; 1(4):265-81. PubMed ID: 10147017
    [TBL] [Abstract][Full Text] [Related]  

  • 52. FDA actions against health economic promotions, 2002-2011.
    Neumann PJ; Bliss SK
    Value Health; 2012; 15(6):948-53. PubMed ID: 22999146
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Pharmacoeconomics--survey and status].
    Pedersen KM
    Ugeskr Laeger; 2003 Apr; 165(16):1670-4. PubMed ID: 12756827
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recent developments in pharmacoeconomic evaluation in Ireland.
    Tilson L; Barry M
    Expert Rev Pharmacoecon Outcomes Res; 2010 Jun; 10(3):221-4. PubMed ID: 20545585
    [No Abstract]   [Full Text] [Related]  

  • 55. Assessment of the opportunities for pharmaceutical manufacturers in emerging markets.
    Anderson T; Olson J; Sobelman D
    J Manag Care Pharm; 2009 Jun; 15(5):396-402. PubMed ID: 19496636
    [No Abstract]   [Full Text] [Related]  

  • 56. Pharmaceuticals and Medical Devices: Cost Savings.
    Steiner DJ;
    Issue Brief Health Policy Track Serv; 2017 Dec; 2017():1-31. PubMed ID: 29361657
    [No Abstract]   [Full Text] [Related]  

  • 57. Pharmaceutical economy and the economic assessment of drugs in France.
    le Pen C
    Soc Sci Med; 1997 Aug; 45(4):635-43. PubMed ID: 9226787
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Regulatory and Economic Considerations of Retinal Drugs.
    Shah AR; Williams GA
    Dev Ophthalmol; 2016; 55():376-80. PubMed ID: 26502165
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Focusing pharmacoeconomic activities: reimbursement or the drug life cycle?
    Langley PC
    Curr Med Res Opin; 2004; 20(2):181-8. PubMed ID: 15006012
    [TBL] [Abstract][Full Text] [Related]  

  • 60. FDA issues warning letter to Abbott over Norvir pricing spin.
    GMHC Treat Issues; 2004; 18(5-6):11. PubMed ID: 15359439
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.